Stryker Corporation $SYK Shares Sold by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. lessened its stake in Stryker Corporation (NYSE:SYK) by 30.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 39,910 shares of the medical technology company’s stock after selling 17,241 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Stryker were worth $14,027,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in SYK. Godfrey Financial Associates Inc. purchased a new position in Stryker in the 4th quarter valued at approximately $26,000. United Financial Planning Group LLC acquired a new stake in Stryker in the third quarter valued at $27,000. CGC Financial Services LLC purchased a new position in shares of Stryker in the fourth quarter valued at $29,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth $30,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in shares of Stryker in the 3rd quarter worth about $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $299.15 on Tuesday. The stock has a fifty day moving average price of $321.00 and a 200 day moving average price of $347.64. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $404.87. The firm has a market capitalization of $114.68 billion, a P/E ratio of 34.62, a PEG ratio of 1.92 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter last year, the firm earned $2.84 EPS. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Activity

In other news, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This represents a 30.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the completion of the transaction, the vice president directly owned 177 shares in the company, valued at $50,170.65. This trade represents a 95.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 323,264 shares of company stock valued at $100,659,489 in the last ninety days. Company insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of several recent research reports. Canaccord Genuity Group dropped their target price on shares of Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price target on shares of Stryker in a research report on Friday, May 1st. Evercore set a $355.00 price objective on Stryker in a research report on Friday, May 1st. BTIG Research reduced their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Sixteen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.